Last reviewed · How we verify
NCT05258123
Ginkgo Biloba Extract in the Treatment of Schizophrenia
NA trial testing Ginkgo Biloba Extract in Schizophrenia in 100 participants. Completed in 15 August 2018.
12 June 2018
Quick facts
| Lead sponsor | Beijing HuiLongGuan Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 15 May 2017 |
| Primary completion | 12 June 2018 |
| Estimated completion | 15 August 2018 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ginkgo Biloba Extract — full drug profile →
- Placebo oral tablet — full drug profile →
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
Beijing HuiLongGuan Hospital
Who can join
Adults 18 to 60, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We investigated the effects of Ginkgo biloba extract on the symptoms and cognitive functioning in patients with schizophrenia
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05258123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ginkgo Biloba Extract
Trials testing the same drug.
- NCT06140888 — Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke · NA · not yet recruiting
- NCT06124703 — Different Dosing Regimens of STOP-AST · NA · unknown
- NCT05591144 — Short-term Oral Prednisone for Acute Subjective Tinnitus · NA · completed
- NCT03425045 — Repetitive Transcranial Magnetic Stimulation for Chronic Subjective Tinnitus · NA · completed
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Beijing HuiLongGuan Hospital trials
Trials by the same sponsor.
- NCT07518264 — Efficacy and Underlying Mechanisms of Group-Based Natural Psychotherapy for Anxiety Disorder · NA · active not recruiting
- NCT07317765 — Research on New Methods and New Models of Rehabilitation Intervention for Cancer Patients Based on Exercise and Psycholo · NA · active not recruiting
- NCT06292156 — tACS Treatment for Cognitive Impairments in Methamphetamine Addicts · NA · completed
- NCT05552014 — Study on the Efficacy Mechanism of Natural Psychotherapy for Neurosis · NA · recruiting
- NCT04055181 — Influence of rTMS on Symptoms and Cognitive Function in Patients With Psychiatric Disorders · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05258123 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing HuiLongGuan Hospital
- Last refreshed: 28 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05258123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing